The pharmaceutical industry has been actively seeking the ideal treatment for hepatitis C for years: a treatment whose features would be an eradication of the virus from the body in 100% of cases.
In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting
In December 2013 the Critical Illness Defi nitions and Geographical Variations Working Party presented their paper, ‘Extending the Critical Path’ to the Staple Inn Actuarial Society.
Winner of the Actuarial Award in Asia, 2013
In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting
En 2013, une neurologie conquérante et innovante voit le jour : la génétique, la biotechnologie, l’imagerie médicale, la neurochirurgie, l’industrie pharmaceutique… les recherches fondamentales et cliniques s’allient
In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting
In 2013, an innovative neurology is emerging which is overcoming all kinds of hurdles: genetics, biotechnology, medical imaging, neurosurgery, the pharmaceutical industry… fundamental and clinical research are uniting
SCOR Global Life, filiale de SCOR SE, rachète un portefeuille d’assurance vie (Value of In-Force) auprès de Mediterráneo Vida, société d’assurance espagnole détenue à 100 % par Banco Sabadell.
SCOR Global Life, filiale de SCOR SE, a conclu un contrat de longévité avec l’assureur britannique Aviva.
SCOR Global Life, filiale de SCOR SE, a conclu un contrat de longévité avec l’assureur britannique Aviva.
Résultats annuels 2013.
